Subclinical Cardiac Changes Following CPX-351 Induction in Adults with Favorable/Intermediate-Risk AML
Chezi Ganzel1, Avraham Frisch2, Ofir Wolach3
1The Hematology and Bone Marrow Transplantation Department The Eisenberg Research and Development Authority Shaare Zedek Medical Center The Hebrew University of Jerusalem Jerusalem Israel.
Abstract:
CPX-351 is associated with reduced non-hematologic toxicity, but its cardiac safety is not well defined. We prospectively assessed ejection fraction (EF) and global longitudinal strain (GLS) in younger adults with AML treated with a single CPX-351-based induction. Median changes were mild and comparable to standard "7 + 3". However, 27% developed clinically significant cardiac changes. These findings support prospective cardiac monitoring and the need for comparative studies. Trial Registration: NCT05599360.
Related Concept Videos
Imaging Studies for Cardiovascular System V: CT
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Mitral Stenosis II: Clinical features and Diagnostic Tests

